Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on August 31, 2023, with the report date of September 5, 2023. The filing discloses significant executive leadership changes, specifically the appointment of a new Chief Financial Officer (CFO) and Chief Legal Officer.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data provided relates to the compensation package for the newly appointed CFO, Scott Burrows:
- Base Salary: $455,000 annually.
- Target Annual Bonus: 40% of base salary.
- Sign-on Bonus: $115,000 (subject to repayment conditions).
- Equity Grants: Options to purchase 10,121,441 shares and 3,373,814 restricted stock units (RSUs).
Material Changes
The primary material change reported is the transition of the Company's financial leadership:
- Appointment: Scott Burrows was appointed CFO, effective September 1, 2023, succeeding Jonathan Alspaugh.
- Departure/Transition: Jonathan Alspaugh is transitioning from CFO to a strategic advisory consulting role.
- Additional Appointment: Heidy Abreu King-Jones was appointed Chief Legal Officer and Corporate Secretary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the Company's business strategy or clinical pipeline. The primary risk disclosed relates to the terms of the new CFO's employment agreement, specifically the severance provisions:
- Standard Involuntary Termination: 12 months of base salary, unpaid bonus, 12 months of COBRA, and accelerated vesting of equity scheduled for the next 12 months.
- Change in Control Termination: 18 months of base salary, full target bonus, 18 months of fully subsidized COBRA, and full acceleration of all equity awards.
Investor Verification Checklist
- Verify the exact vesting schedules and performance conditions for the 10.1 million stock options and 3.3 million RSUs granted to Scott Burrows.
- Confirm the status of Jonathan Alspaugh's transition to a consulting role and any associated ongoing compensation.
- Review the full text of the Offer Letter (Exhibit 10.1) for complete details on termination triggers and "good reason" definitions.
- Check subsequent filings for any impact of this leadership change on the Company's cash burn rate or capital raising plans.